



Published in final edited form as:

Int J Gynecol Cancer. 2020 June ; 30(6): 772–776. doi:10.1136/ijgc-2019-000909.

Prevalence and predictors of HIV screening in invasive cervical cancer, an AIDS-defining illness: a 10-year retrospective cohort study

Jill K ALLDREDGE, MD¹, Marie-Claire MATSUO, MD¹, Priya A PATEL², Teresa C. LONGORIA, MD¹, Katherine E. COAKLEY, MD¹, Christine E. MCLAREN, Ph.D.³, Leslie M. RANDALL, MD, MAS¹

¹-University of California, Irvine, Department of Obstetrics and Gynecology, 101 The City Dr South, Orange, CA 92868

²-University of California, Irvine, School of Medicine, 1001 Health Sciences Rd, Irvine, CA 92617

³-University of California, Irvine, Department of Epidemiology, 1001 Health Sciences Rd, Irvine, CA 92617

Abstract

Background: Invasive cervical carcinoma is associated with an HIV prevalence of >0.1%. Opt-out HIV screening is recommended and cost-effective for cancer populations exceeding this threshold. HIV status is also prognostic for cancer-specific survival, but compliance with HIV screening is poor in the US and abroad.

Objectives: This study aims to describe HIV screening practices in a US comprehensive cancer center, as we anticipate this is low. To guide quality improvement in HIV screening, we identify patient and tumor characteristics which predict compliance with screening.

Study Design: Women treated for invasive cervical cancer of any stage between 2007 and 2017 at two institutions were identified by cancer registry and billing data. Women with incomplete data for age, race, ethnicity, payer, histology, stage, pregnancy, drug use, and HIV testing status, or with lack of a newly diagnosed cervical cancer or Gynecologic Oncology evaluation were excluded. Univariate logistical regression was performed to assess predictors of completed HIV screening.

Results: Of 1483 patients identified, 492 were eligible. No patients had a diagnosis of pre-existing HIV. HIV screening was completed within 30 days of Gynecologic Oncology evaluation in 28/492 (5.6%) women. HIV screening was documented within the preceding 12 months in 10/492 (2%) women. The cumulative screening rate was 7.6%. On univariate analysis, race, ethnicity, histology, and payer status were not associated with screening. Every 5-year increase in age was associated with a lower chance of screening (OR 0.86, 95%CI 0.75 – 0.97, p=0.015), as was earlier stage at diagnosis (OR 0.43, 95% CI 0.22–0.86, p=0.017). Only 9/492 (1.8%) of

Corresponding author: Jill Alldredge MD, 333 City Blvd Suite 1400, Orange, CA 92868, Cell: 505-350-9921 / Office: 714-456-6807, Fax: 714-456-8360, jallred@uci.edu.

Conflicts of Interest: The authors report no conflicts of interest

Presentation information: 35th Annual Meeting of the Western Association of Gynecologic Oncologists, Park City, UT, June 2018 – oral presentation

women in the cohort had a pregnancy during, or antecedent to, her cervical cancer diagnosis. Within this group, HIV screening was significantly more predictive of screening compliance (OR 10.57, 95%CI 2.71–41.14, $p=0.0007$). Only 8/491 (1.6%) of women in the cohort had active or former drug use, but within this group HIV screening was performed more frequently compared to no prior use (OR 22.7, 95% CI 5.2–99.2, $p<0.0001$).

Conclusion: Despite CDC recommendations for HIV screening in AIDS-defining cancers, compliance remains low. In our centers, factors including earlier age, advanced stage, active pregnancy at diagnosis, and any drug use history were predictive of greater compliance with screening. These data will inform a tailored intervention to improve compliance with HIV screening in our population.

Condensation:

Screening for HIV in women with newly diagnosed invasive cervical cancer occurs rarely and offers an opportunity for quality improvement in US Gynecologic Oncology practices.

Keywords

HIV screening; cervical cancer; quality improvement

Introduction

Invasive cervical carcinoma (ICC) is the second most common cancer in women worldwide, with over 83% of cases occurring in the developing world¹. In the US in 2016, there were 12,990 new cases and 4,120 deaths and cervical cancer remains the second leading cause of cancer death in young women age 20–39 years². It is well established that human papilloma virus (HPV) DNA can be detected in 95–100% of invasive cervical cancer specimens and that this sexually transmitted virus is an essential causative mechanism. Women with HIV-positivity, particularly with immunosuppression, are more likely to contract a high-risk HPV infection and this is more likely to be persistent and cause cervical dysplasia or an invasive cervical cancer^{3,4}.

At a threshold of HIV prevalence $>0.1\%$, it is considered an autoimmune deficiency syndrome (AIDS)-defining cancer (ADC). Invasive cervical cancer is unique in that it is the only gynecologic malignancy listed by the Center for Disease Control as an ADC⁵. The prevalence of HIV was 1.2% in a US study of all AIDS-defining cancers, however in the small subset of women with cervical cancer only 23/245 (9.4%) were screened for HIV⁶. Similarly, in a European assessment of three ADC's, ICC had an HIV-seroprevalence of 1.7%, with screening performed in only 6/57 (10.5%) of patients.

In the National Comprehensive Cancer Network Cervical Cancer Guidelines, consideration of HIV testing is encouraged in the workup of a newly diagnosed ICC patient⁷. Additionally, the HIV Indicator Disease Across Europe (HIDES) trial supports that invasive cervical cancer is among a small handful of diseases that merit HIV testing upon diagnosis⁸. Despite these US and European recommendations, screening compliance remains low.

The primary objective of this study was therefore to establish the frequency of HIV screening in women with newly diagnosed ICC in a large comprehensive US Gynecologic Oncology practice, as well as to determine any predictive factors for screening compliance to guide efforts in quality improvement.

Materials and Methods

Data Source

For this retrospective cohort study, we identified women over age 18 using institutional tumor registries as well as billing codes (ICD-9 180.9 and ICD-10 C53.9) for invasive cervical cancer. Women were included if they had a newly diagnosed invasive cervical cancer, had been evaluated by a University of California, Irvine Gynecologic Oncologist at one of three sites of practice throughout the Orange County and southern Los Angeles areas. To reflect the implementation of the 2016 CDC HIV screening guidelines, this study spanned 1/2007 through 9/2017. Women were excluded if their billing code did not accurately reflect a newly diagnosed invasive cervical cancer diagnosis (non-cervical primary cancer, cervical dysplasia, recurrent cancer), medical records were incomplete, or they presented for initial care with someone other than a Gynecologic Oncologist at our institution.

Of 1483 women identified by cancer registry or billing data, 991 of these were excluded. Of these 450 had no new ICC diagnosis, 263 were seen by an outside provider at diagnosis, 160 were prior to the 1/2007 initiation date, and 118 had incomplete medical records. This resulted in 492 women included in the analysis (Figure 1).

This study was approved by the institutional review boards at University of California, Irvine, the Cancer Prevention and Treatment Center of St Joseph's Hospital, and the MemorialCare Health System, all of whom waived the requirement for informed consent.

Study Objectives

The aim of this study was to establish the baseline frequency with which HIV screening is being performed. HIV screening was considered complete if it was documented in the clinical notes, an HIV-1/2 antibody test by enzyme-linked immunosorbent assay was resulted within 12 months prior to diagnosis, or if an HIV-1/2 antibody test by enzyme-linked immunosorbent assay was ordered within 30 days of the encounter for newly diagnosed ICC. Possible confounding variables were assessed including age, race, ethnicity, payer status, pregnancy in the preceding 12 months or at ICC diagnosis, former or active drug use, and tumor factors including histology and stage. Pregnancy was established using ICD9 and ICD10 codes or review of medical records, with the timing of the pregnancy, HIV testing, and cervical cancer diagnosis noted temporally. Drug use was established using ICD9 or ICD10 codes for drug or substance dependency or reviewed of medical records. Identification of variables and HIV testing was limited to the available paper or electronic medical records associated with the initial encounter with a UCI Gynecologic Oncologist and patients were only included once if they had visits with multiple sites or providers within our group.

Statistical Analyses

Frequency of HIV testing was the primary endpoint of this study. We employed descriptive statistics to define the screening frequency in newly diagnosed women and in the 12 months preceding diagnosis. Univariate modeling was performed comparing demographic, tumor, drug and pregnancy variables between those patients who were screened and were not screened for HIV to determine the predictors of HIV testing. Association(s) between categorical variables and screening performance were reported as an odds ratio with a 95% confidence interval. Wald-Chi square statistics were used to analyze age effect on screening performance. For statistical analysis, we used SAS v9.4 Software⁹.

Results:

Screening Frequencies

Of the 1483 women identified by registry and billing data, 492/1483 met inclusion criteria, as described in figure 1. A total of 38/492 (7.6%) patients had some form of HIV screening completed in association with their new ICC diagnosis. No women had known pre-existing HIV at diagnosis. Of these, 10/492 (2%) had documented HIV screening performed within 12 months prior to diagnosis, and 28/492 (5.6%) had a new screening test ordered within 30 days of diagnosis (Figure 2).

Of those with existing screening preceding their ICC diagnosis, 3/38 (37.8%) were documented only in the clinical notes while 35/38 (92%) were found only in laboratory reports within the paper or electronic medical records. Demographic factors, tumor characteristics, drug use and pregnancy are described in Figure 2.

The mean age for the cohort was 50.4 (+/- 14.9). The majority of the population was white (62%) and overall 60% of women identified as non-Hispanic. Detailed information regarding payer source at the time of diagnosis were obtained, with grouped frequencies of 18% receiving federal funding, 39% state funding, 36% private funding and 5% self-pay. Tumor characteristics included 66% were squamous cell carcinomas and 25% adenocarcinoma, with 9% of more rare histologies, and 56% were stage 1, 23% stage 2, 14% stage 3 and 9% stage IV. Only 7/492 (1.4%) women were pregnant at the time of ICC diagnosis. Of these, no new testing was ordered and only 2/7 (28.5%) had existing HIV screening documented within the prior 12 months. An additional 2 women had a pregnancy within the 12 months preceding diagnosis but not at diagnosis – of these, 0/2 had HIV documented with their pregnancy however 2/2 (100%) had new HIV screening performed within 30 days of cancer diagnosis. If pregnancy at any time during the preceding 12 months is assessed cumulatively, this would encompass 9/492 (1.8%) women with a screening performed in 4/9 (44.4%) in this population.

Predictive Factors for Screening

No demographic factors except age significantly predicted performance of HIV screening (Figure 3). The age effect on screening performance was evaluated with an OR = 0.73 (95% CI, 0.57–0.94, p = 0.015) for every 10-year increase in age. Tumor histology was not a significant predictor. Tumor stage, defined as early (FIGO stage I-II) and advanced (stage

IIIV) had an OR = 0.43 (95% CI 0.22–0.86, $p = 0.017$), suggesting that more advanced cancers were predictive for screening. A total of 9/492 (1.8%) women in the cohort had a pregnancy during, or antecedent to, her cervical cancer diagnosis. Within this pregnancy cohort, HIV screening was significantly correlated with performance of HIV screening, OR = 10.57 (95% CI 2.71 – 41.17, $p = 0.0007$). The use of drugs, either current or former, was predictive for performance of HIV screening with OR=22.7 (95% CI 5.2–99.2, $p<0.0001$).

Structured Discussion/Comments:

Principal Findings

Our study allowed a broad definition of HIV screening to include the 12 months prior and the 30 days after HIV screening, with an overall rate of screening at 7.6% screening rate for HIV. In our cohort of patients under the care of academic US Gynecologic Oncologists, we found that younger age, advanced stage, active pregnancy at diagnosis, and former or active drug use were predictive of greater compliance with screening

Results Discussion

The screening rate of 7.6% our population is similar to the low incidence of screening noted in other smaller studies, including 9.4% in a US study in which ICC was one of many studied cancers, and 10.5% in a Swiss study of four ADCs¹⁰¹¹.

Patient and tumor characteristic including younger age, advanced stage, active pregnancy at diagnosis, and former or active drug use were predictive of greater compliance with screening. The influence of pregnancy on HIV screening is not unexpected given the widespread uptake of routine opt-out screening during prenatal care. Similarly, practitioners may correctly identify drug use as a risk for HIV infection and cervical cancer risk. Despite this, however, the rate of screening even in those with pregnancy at diagnosis or drug use were relatively low. This may represent a limitation of the study in capturing all relevant screening, which may have been at outside facilities associated with the care of these specific conditions.

Clinical Implications

Previous studies stress the importance of HIV testing in newly diagnosed cancer patients, largely because earlier diagnoses of HIV allows for better management of both disease processes¹². As of 2013, the most recent year when such data was available, more than 1.2 million individuals in the United States are infected with HIV, with up to 13% being unaware of their status⁵. Additionally, many of these individuals are diagnosed at late stages in the disease, with almost 40% of them progressing to AIDS within a year of their initial diagnosis. HIV infected patients also have worse cancer outcomes than HIV uninfected patients with the same cancers. Testing patients for HIV when they are initially diagnosed with ICC could help to better select their chemotherapy and antiretroviral regimens, thus leading to improved outcomes for these patients¹⁰. This speaks to a pressing need to increase HIV screening programs within the US.

In 2006, the Center for Disease Control (CDC) and US Preventative Services Task Force (USPSTF) recommended opt-out HIV screening in areas with an HIV infection prevalence exceeds 0.1%. In the US, this translates to at least once for all individuals age 13–64 years of age, with annual screening advised for those in a high-risk group¹³. This high-risk group includes those with ICC, as the incidence in AIDS-defining cancers is 1.2%, as well as in those with active injection drug use and in pregnancy.

The 2006 CDC recommendations emphasize an opt out strategy for HIV testing among the general population, an approach which has been proven to be cost effective^{5,14}. Within this model, the consent for HIV testing should be integrated into a consent for general medical care, while still allowing a patient to specifically decline the HIV test. Many obstacles still remain for implementing wide spread opt-out practices, including physicians' objections and state laws requiring a separate consent. However, opt-out testing may prove to be more successful when targeted at a specific population, such as women diagnosed with cervical cancer, and may play a role in reducing mortality and morbidity within this group¹⁵.

Research Implications

Identification of deficiencies in provider HIV screening practices and clarification of the patient and tumor factors that underlie these screening choices may inform quality improvement efforts. This cohort was intended to inform interventions targeted at provider and patient education as an area of future research to improve patient care.

Strengths and Limitations

Our study is unique in that it includes those with invasive cervical cancer only and includes a large sample of patients. Additionally, it deliberately assessed screening patterns after the 2006 CDC and USPSTF recommendations. This cohort represents a range of practice settings, including public, private, and community hospitals, all under the care of one group of academic Gynecologic Oncologists. While the retrospective cohort design facilitates evaluation of the relatively rare exposure of cervical cancer, the most evident weakness of the design is the limitation of both paper and electronic medical records systems in providing all possible data.

Conclusions

In light of the fact that screening is cost effective, has the potential to alter treatment courses, and improve patient outcomes, implementing HIV screening for newly diagnosed cervical cancer patients presents itself as a beneficial and feasible intervention that is grossly underutilized in the US and abroad. Our study supports that screening rates are very low despite CDC and NCCN recommendations. These data may facilitate interventions to improve compliance with HIV screening.

Acknowledgements

We would like to thank the University of California, Irvine Department of Obstetrics and Gynecology for their financial support of this project.

Sources of financial support:

UCI Obstetrics and Gynecology Department

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA: a cancer journal for clinicians*. 2005;55(2):74–108. [PubMed: 15761078]
2. Health NI. Surveillance, Epidemiology and End Results Program. 2016; <https://seer.cancer.gov/statfacts/html/cervix.html>. Accessed 2.8.2017.
3. Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. *American journal of obstetrics and gynecology*. 1998;178(5):982–986. [PubMed: 9609571]
4. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. *The New England journal of medicine*. 1997;337(19):1343–1349. [PubMed: 9358128]
5. Prevention CfDCa. HIV in the United States: At A Glance. 2016; <https://www.cdc.gov/hiv/statistics/overview/ataglance.html>. Accessed 3/1/2017.
6. Hwang JP, Granwehr BP, Torres HA, et al. HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center. *Journal of oncology practice*. 2015;11(5):384–390. [PubMed: 26243649]
7. Network NCC. Cervical Cancer Guidelines. 2016.
8. Sullivan AK, Raben D, Reekie J, et al. Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). *PLoS One*. 2013;8(1):e52845. [PubMed: 23341910]
9. SAS Enterprise Miner 13.1. [computer program]. Cary, NC..
10. J H. HIV Testing in Patients with care at the Initiation of Therapy at a large US Comprehensive Cancer Center. *J Oncolo Practice*. 2015;11(5):384–391.
11. Mosimann V, Cavassini M, Hugli O, et al. Patients with AIDS-defining cancers are not universally screened for HIV: a 10-year retrospective analysis of HIV-testing practices in a Swiss university hospital. *HIV Med*. 2014;15(10):631–634. [PubMed: 25102762]
12. Li. Testing for Human Immunodeficiency Virus Among Cancer Survivors Under 65 in the United States. *Prev Chronic Dis*. 2014;11(E200):140274.
13. Branson BHH, Lampe M, et al. Revised Recommendations for HIV Testing of Adults, Adolescents and Pregnant Women in Health-Care Settings. *MMWR*. 9/22/2006;55(RR 14);1–17.
14. G S. Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy. *NEJM*. 2005;352:570–585. [PubMed: 15703422]
15. Chiao EY, Dezube BJ, Krown SE, et al. Time for oncologists to opt in for routine opt-out HIV testing? *JAMA*. 2010;304(3):334–339. [PubMed: 20639567]

AJOG at a glance:

- A.** Despite international guidelines for HIV screening in newly diagnosed cervical cancers, the compliance of US Gynecologic Oncology providers with screening has not been well studied. No study has evaluated predictive factors for screening in this cohort.
- B.** Only 7.6% of women with newly diagnosed cervical cancer were screened for HIV in our population. Several factors such as younger age, later cancer stage, recent pregnancy or drug use history may predict the performance of screening however this overall rate is very low.
- C.** Women with newly diagnosed cervical cancer are high risk populations who merit HIV screening. With a significantly more robust sample size than any prior assessment in the US or abroad, screening in our population was quite low. This identifies an area of practice for focused quality improvement.




Figure 1.
Study population flow diagram

	n	%
Pre-existing HIV diagnosis	0	0%
Documented HIV screen in past 12 months	10	2%
New HIV screen at time of diagnosis	28	5.6%
No screening done	454	92.3%

Figure 2.
HIV screening practices

Demographics	Screening	No screening
Totals, N	38	454
Age, mean	42.6 years	48.6 years
Race, N(%)		
White	26 (5.2%)	279 (56.7%)
African American	2 (0.4%)	13 (2.9%)
American Indian/Alaska Native	0 (0%)	3 (0.6%)
Asian/Pacific Islander	6 (1.2%)	69 (15.2%)
Not identified	3 (0.7%)	90 (19.8%)
Ethnicity, N(%)		
Non-Hispanic	20 (4.6%)	273 (55.4%)
Hispanic	17 (3.4%)	174 (35.3%)
Not identified	0 (0%)	7 (1.5%)
Insurance status/category, N(%)		
Self Pay	5 (1.0%)	88 (17.8%)
Federal funding (Medicare)	5 (1.0%)	172 (40.6%)
State funding (Medical)	4 (0.8%)	20 (4.1%)
Private	24 (4.9%)	171 (34.7%)
Other	0 (0%)	3 (0.7%)
Tumor Histology, N(%)		
Squamous cell carcinoma	25 (5.1%)	300 (60.9%)
Adenocarcinoma NOS	8 (1.6%)	116 (23.6%)
Adenosquamous carcinoma	4 (0.8%)	16 (3.3%)
Other	0 (0%)	22 (4.5%)
FIGO Stage at diagnosis, N(%)		
Stage 1	15 (3.0%)	259 (52.6%)
Stage 2	8 (1.6%)	95 (19.3%)
Stage 3	10 (2.0%)	60 (12.1%)
Stage 4	5 (1.0%)	40 (8.1%)
Pregnancy (N, %)		
Any pregnancy in past 12mo, N(%)	4 (44.4%)	5 (55.6%)
Active pregnancy at diagnosis, N(%)	2 (28.6%)	5 (71.4%)
Drug Behavior (N, %)		
Never use	33 (6.7%)	450 (92.1%)
Former use	4 (0.8%)	1 (0.2%)
Active use	1 (0.2%)	2 (0.4%)

Figure 3.
Patient and tumor characteristics

Predictor	OR (95%CI)	P
Race (White vs non-white)	1.54 (0.74 - 3.18)	0.24
Age (Every 5 year increase)	0.86 (0.75 - 0.97)	0.015
Ethnicity (Hispanic vs non-Hispanic)	1.45 (0.75 - 2.81)	0.27
Tumor Histology (SCC vs non-squamous)	0.99 (0.49 - 1.98)	0.97
Stage (Early vs advanced)	0.43 (0.22 - 0.86)	0.017
Current/former pregnancy past 12mo (Yes vs no)	10.57 (2.71 – 41.14)	0.0007
Insurance status (Insured vs self pay)	0.39 (0.13 - 1.21)	0.10
Drug Use (Any drug history vs never)	22.7 (5.2 - 99.21)	<0.0001

Figure 4.
Odds Ratios for Screening Predictors




Figure 5.
Summary of HIV screening and predictive factors

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript